Glioblastoma (GBM) is the most malignant brain tumor with notorious heterogeneous, infiltrative and chemoresistance. Here, we developed a hydrogel-based drug delivery system for sequential and sustainable local drug delivery with rheological properties that favor applications to the brain. We designed methotrexate (MTX) to release prior to gemcitabine (Gem). Using CEST, the multicomponent of hydrogel matrix could be detected at 3 T, including the contrast of loaded drugs (5.4%) at 2.2-2.4 ppm and liposomal hydrogel matrix at -3.6 ppm in vitro. Furthermore, it showed combined cytotoxicity on U87 cells, demonstrating its potential on CEST MRI guided local treatment.